Ikarian Capital »

Eli Lilly & Co. shares owned by Ikarian Capital

Quarter-by-quarter ownership of Eli Lilly & Co. (LLY) shares owned by Ikarian Capital from 13F filings

Historical chart of Ikarian Capital investment in Eli Lilly & Co.

Tip: Access up to 7 years of quarterly data

All positions including Eli Lilly & Co. held by Ikarian Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Eli Lilly & Co. by Ikarian Capital

Quarter filed Position value Share count Share price at filing
2023-12-31 $41M 70k 582.92
2023-09-30 $659k 1.2k 537.13
2021-06-30 $1.3M 5.7k 229.70
2021-03-31 $23M 125k 186.82
2020-12-31 $17M 100k 168.84

More positions owned by Ikarian Capital

Argenx Se Sponsored Adr (ARGX)
Krystal Biotech Call Option (KRYS)
Cytokinetics Com New (CYTK)
Alnylam Pharmaceuticals Call Option (ALNY)
Spdr Ser Tr S&p Biotech Put Option (XBI)
Crispr Therapeutics Namen Akt (CRSP)
Eli Lilly & Co. Put Option (LLY)
Sarepta Therapeutics (SRPT)
Prothena Corp SHS Call Option (PRTA)
Amylyx Pharmaceuticals (AMLX)
Nuvalent Inc-a (NUVL)
Immunovant (IMVT)
Crinetics Pharmaceuticals In (CRNX)
Soleno Therapeutics (SLNO)
Eyepoint Pharmaceuticals Com New (EYPT)

View all positions for Ikarian Capital

Top funds holding Eli Lilly & Co.

Lilly Endowment
Vanguard Group
Pnc Financial Services
PRIMECAP Management Company
T. Rowe Price Associates
Jpmorgan Chase & Co
State Farm Mutual Automobile Insurance Company
Wellington Management Company
Bank of America Corporation
Norges Bank Investment Management
Jennison Associates
Legal & General Group
Bank of New York Mellon
Alliancebernstein
Goldman Sachs Group

View all funds holding Eli Lilly & Co.